The latter even included modern targeted agents never used to treat the donor patient’s tumor, i.e., crizotinib and lorlatinib, inhibiting ALK kinase (both CHLA-15 and CHLA-20 harbor the same ALKR1275Q activating mutation), or the MEK inhibitor trametinib (Fig. 1e). The gene discussed is MAP2K7; the disease is neoplasm.